Erythropoietin (EPO) vs PE 22-28
Updated August 3, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of Erythropoietin (EPO) and PE 22-28 (also searched as PE 22-28 vs Erythropoietin (EPO)) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
Erythropoietin (EPO) centers on healing, while PE 22-28 leans toward metabolic. On indexed research, Erythropoietin (EPO) is ahead (Erythropoietin (EPO): 19 studies, Human evidence; PE 22-28: 17, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •Erythropoietin (EPO) is strongest for healing; PE 22-28 for metabolic.
- •Evidence: Erythropoietin (EPO) Human evidence (19 studies) vs PE 22-28 Human evidence (17).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
Stimulates RBC production | Treats anemia
Metabolic regulation | Vascular health
Erythropoietin (EPO) vs PE 22-28: side-by-side
| Metric | Erythropoietin (EPO) | PE 22-28 |
|---|---|---|
| Class | Healing | Metabolic |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Human evidence | Human evidence |
| Studies indexed | 19 | 17 |
| Research level | Well Studied | Limited Research |
| Strongest effect | Healing & recovery | Metabolic & appetite |
| Healing & recovery | 4.0▲ | 1.0 |
| Muscle & body comp | 0.0 | 0.0 |
| Metabolic & appetite | 3.0▲ | 3.0▲ |
| Neuro & mood | 0.0 | 0.0 |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 0.0 | 2.0▲ |
| Skin & aesthetics | 0.0 | 0.0 |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | Erythropoietin (EPO) | PE 22-28 |
|---|---|---|
| Mechanism | Erythropoietin receptor agonist | — |
| Route | Subcutaneous injection | — |
| Half-life | ~4–13 hours | — |
| Time to peak | 5–24 hours | — |
| Duration of action | 1–2 days | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Erythropoietin (EPO)?
Erythropoietin (EPO) is a glycoprotein hormone that stimulates red blood cell production in bone marrow, used clinically for anemia and studied in hematology and metabolic research.
Full Erythropoietin (EPO) profile, mechanism & studies →What is PE 22-28?
### Summary PE 22-28 is a peptide that has garnered attention in various research contexts, particularly in relation to vascular health and metabolic conditions. Its potential implications in gestational diabetes and placental function are areas of ongoing investigation.
Full PE 22-28 profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | Erythropoietin (EPO) | 4.0/5 effect signal |
| Metabolic | Even | Both ~3.0/5 |
| Inflammation | PE 22-28 | 2.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack Erythropoietin (EPO) and PE 22-28?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
Erythropoietin (EPO) vs PE 22-28: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
Erythropoietin (EPO) has 19 approved studies indexed (Human evidence), and PE 22-28 has 17 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is Erythropoietin (EPO) or PE 22-28 better?
It depends on your goal. Erythropoietin (EPO) is strongest for healing; PE 22-28 for metabolic. Erythropoietin (EPO) has more indexed studies (19). See the goal-by-goal breakdown above.
Is Erythropoietin (EPO) or PE 22-28 better for weight loss?
They score similarly on the metabolic/appetite axis in the community data.
Which has more research, Erythropoietin (EPO) or PE 22-28?
Erythropoietin (EPO) has 19 approved studies indexed (Human evidence); PE 22-28 has 17 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack Erythropoietin (EPO) and PE 22-28?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of Erythropoietin (EPO) vs PE 22-28?
Erythropoietin (EPO): no community-reported effects logged yet. PE 22-28: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is Erythropoietin (EPO) or PE 22-28 FDA-approved?
Erythropoietin (EPO) is a research-use compound and is not FDA-approved. PE 22-28 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is PE 22-28 better than Erythropoietin (EPO)?
For metabolic, PE 22-28 has the edge; for healing, Erythropoietin (EPO) does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Erythropoietin (EPO) and PE 22-28 are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed August 3, 2026.